Podocyte dysfunction in atypical haemolytic uraemic syndrome

被引:37
作者
Noris, Marina [1 ]
Mele, Caterina [1 ]
Remuzzi, Giuseppe [1 ]
机构
[1] IRCCS Ist Ric Farmacol Mario Negri, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24020 Bergamo, Italy
关键词
PROTEIN-KINASE-C; COMPLEMENT FACTOR-H; EXPERIMENTAL MEMBRANOUS NEPHROPATHY; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-C; THROMBOTIC MICROANGIOPATHY; SIGNAL-TRANSDUCTION; INTRACELLULAR CA2+; ENDOTHELIAL-CELLS; VEGF INHIBITION;
D O I
10.1038/nrneph.2014.250
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Genetic or autoimmune defects that lead to dysregulation of the alternative pathway of complement have been associated with the development of atypical haemolytic uraemic syndrome (aHUS), which is characterized by thrombocytopenia, haemolytic anaemia and acute kidney injury. The relationship between aHUS, podocyte dysfunction and the resultant proteinuria has not been adequately investigated. However, the report of mutations in diacylglycerol kinase epsilon (DGKE) as a cause of recessive infantile aHUS characterized by proteinuria, highlighted podocyte dysfunction as a potential complication of aHUS. DGKE deficiency was originally thought to trigger aHUS through pathogenetic mechanisms distinct from complement dysregulation; however, emerging findings suggest an interplay between DGKE and complement systems. Podocyte dysfunction with nephrodtic-range proteinuria can also occur in forms of aHUS associated with genetic or autoimmune complement dysregulation without evidence of DGKE mutations. Furthermore, proteinuric glomerulonephritides can be complicated by aHUS, possibly as a consequence of podocyte dysfunction inducing endothelial injury and prothrombotic abnormalities.
引用
收藏
页码:245 / 252
页数:8
相关论文
共 50 条
[31]   Haemolytic-uraemic syndrome in a heroin addict [J].
Peces, R ;
Díaz-Corte, C ;
Baltar, J ;
Seco, M ;
Alvarez-Grande, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (12) :3197-3199
[32]   Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab [J].
Gately, Ryan ;
San, Aye ;
Kurtkoti, Jagadeesh ;
Parnham, Alan .
NEPHROLOGY, 2017, 22 :32-35
[33]   Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study [J].
Portoles, Jose ;
Huerta, Ana ;
Arjona, Emilia ;
Gavela, Eva ;
Aguera, Marisa ;
Jimenez, Carlos ;
Cavero, Teresa ;
Marrero, Domingo ;
Rodriguez de Cordoba, Santiago ;
Diekmann, Fritz .
CLINICAL KIDNEY JOURNAL, 2021, 14 (04) :1173-1180
[34]   Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort [J].
Mallett, A. ;
Hughes, P. ;
Szer, J. ;
Tuckfield, A. ;
Van Eps, C. ;
Cambell, S. B. ;
Hawley, C. ;
Burke, J. ;
Kausman, J. ;
Hewitt, I. ;
Parnham, A. ;
Ford, S. ;
Isbel, N. .
INTERNAL MEDICINE JOURNAL, 2015, 45 (10) :1054-1065
[35]   A rare cause of the pulmonary-renal syndrome: a case of atypical haemolytic-uraemic syndrome complicated by pulmonary haemorrhage [J].
Derebail, Vimal K. ;
Parikh, Palak ;
Jennette, J. Charles ;
Kshirsagar, Abhijit V. .
CLINICAL KIDNEY JOURNAL, 2008, 1 (06) :417-419
[36]   Eculizumab treatment of atypical haemolytic uraemic syndrome: results from the largest prospective clinical trial to date [J].
LE weekers ;
JM Campistol ;
M Espinosa ;
AO Gaber ;
J Menne ;
E Minetti ;
F Provot ;
E Rondeau ;
M Ogawa ;
CL Bedrosian ;
M hourmant .
Critical Care, 18 (Suppl 1)
[37]   Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? [J].
Johnson, Sally ;
Waters, Aoife .
IMMUNOBIOLOGY, 2012, 217 (02) :235-243
[38]   Recurrence of haemolytic uraemic syndrome after renal transplantation [J].
Loirat, Chantal ;
Fremeaux-Bacchi, Veronique .
CURRENT OPINION IN ORGAN TRANSPLANTATION, 2007, 12 (05) :496-502
[39]   Postpartum haemolytic uraemic syndrome associated with antiphospholipid antibody [J].
Huang, JJ ;
Chen, MW ;
Sung, JM ;
Lan, RR ;
Wang, MC ;
Chen, FF .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (01) :182-186
[40]   Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study [J].
Menne, Jan ;
Delmas, Yahsou ;
Fakhouri, Fadi ;
Kincaid, John F. ;
Licht, Christoph ;
Minetti, Enrico E. ;
Mix, Chris ;
Provot, Francois ;
Rondeau, Eric ;
Sheerin, Neil S. ;
Wang, Jimmy ;
Weekers, Laurent E. ;
Greenbaum, Larry A. .
CLINICAL KIDNEY JOURNAL, 2019, 12 (02) :196-205